University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Phase 2 study of the mTOR inhibitor everolimus in combination with bevacizumab in patients with sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors.
Official Title

Phase 2 study of the mTOR inhibitor everolimus in combination with bevacizumab in patients with sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors.

Description

Participants in this research study have a tumor called malignant peripheral nerve sheath tumor (MPNST) which has not responded to treatment with one or more prior chemotherapy treatments and cannot be completely removed by surgery (unresectable), or has spread to other areas of the body (metastasized). The purpose of this study is to determine how well participants with MPNSTs respond (experience tumor shrinkage or lack of further tumor growth) to treatment with everolimus in combination with bevacizumab.

Approximately 5 people will take part in this study conducted by investigators at the University of Iowa. A maximum of 25 people will take part in this study nationwide.

Start Date
June 3, 2013
End Date
February 1, 2016
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Melanie Frees, (319) 356-1228

Department
Hematology/ Oncology
Keywords
201303715 ; cancer ; Enter keyword ; malignant peripheral nerve sheath tumors ; Milhem ; peripheral nerve ; Phase two ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.